The single biggest demand event in modern medicine is the GLP-1 wave — the obesity and diabetes drugs the whole world suddenly wants. So here's something surprising: it barely shows up in a small-molecule patent radar. That's not a gap in the data. It's the most important thing the data tells you.
From the Knitify Pharma Demand Radar — our running read on where pharmaceutical demand is heading. We publish the observations; the method behind them stays in-house.
The science: these aren't pills, they're peptides
GLP-1 drugs like semaglutide and tirzepatide aren't small molecules you can stamp out in a chemical plant. They're peptides — short chains of amino acids linked in a precise order, much larger than an ordinary oral drug. In the taxonomy of medicines, peptides sit in the awkward middle. A classic small molecule is a compact structure a chemist can assemble in a reaction vessel and purify to a powder. A biologic like a monoclonal antibody is a large protein grown inside living cells. A peptide is neither: too big to behave like a tidy small molecule, yet not something you simply brew wholesale in a bioreactor the way an antibody is. That in-between position is exactly what makes them hard to produce.
A common way to make a therapeutic peptide at scale is solid-phase peptide synthesis, a slow, stepwise chemical process that consumes enormous volumes of solvent and reagent and is hard to run at industrial volume; and the largest-volume peptides use a hybrid route instead — growing the backbone by recombinant fermentation, then finishing it chemically. [1] The upshot is that the GLP-1 boom doesn't lean on the same factories, feedstocks, or chemical know-how as the small-molecule drugs that fill most pharmacy shelves — it runs on a parallel supply chain that the small-molecule world rarely touches.
So a small-molecule radar's near-silence on GLP-1 isn't a miss — it's telling you the demand has moved to a completely different kind of chemistry, on a completely different supply chain.
How a peptide actually gets built
Solid-phase synthesis is deceptively simple in concept and brutal in practice. The peptide is grown one amino acid at a time while anchored to tiny beads of insoluble resin. Each amino acid arrives with its reactive groups masked by protecting groups so that only the one intended bond can form. A single cycle goes: couple the next protected amino acid onto the growing chain, wash away the excess, strip off the temporary protecting group to expose the next attachment point, wash again, and repeat. Anchoring the chain to a solid bead is the whole trick — it lets you flood the reaction with excess reagent to drive each step, then simply rinse the leftovers away instead of purifying an intermediate every time.
Do that dozens of times in the correct order and you have the peptide backbone. Then it has to be cleaved off the resin, have its remaining protecting groups removed, and — for many drugs — be folded into the right three-dimensional shape before it is anything more than a linear string. Each finishing step is its own chemistry with its own failure modes. Most of the assembly is a repetitive, automatable loop — but its small imperfections compound.
Why scaling it is the hard part
The problem is arithmetic. Every coupling and deprotection step is very good but not perfect, and yield losses multiply across a long chain. A tiny shortfall per cycle, repeated across a molecule with many residues, quietly erodes the correct full-length product — and generates a crowd of closely related impurities: chains missing a residue, chains that picked up an extra one, chains that reacted in the wrong place. Because those byproducts look chemically almost identical to the drug, separating them out is a heavy purification burden that can dominate the back end of the process and cap how much finished material a line can actually deliver.
Then there is the sheer material intensity. The wash-and-repeat rhythm that makes the chemistry reliable also makes it thirsty: solid-phase peptide synthesis can generate on the order of thousands of kilograms of solvent waste for every kilogram of product, and raw materials — the protected amino acids and coupling reagents — dominate the cost. Scaling this isn't like turning up a dial on a small-molecule reactor. It means more solvent handling, more waste treatment, more high-purity reagent, and more purification capacity, all at once — a chemistry that is convenient at lab scale becoming a logistics and capital problem at the metric-ton scale a global drug demands.
The bottleneck is capacity, and capacity is capital
Here is the pivotal fact about the GLP-1 event: the science is settled. Nobody is racing to discover semaglutide or tirzepatide — they exist, they work, and their structures are known. The race is entirely about making enough of them, and that reframes the whole demand question. When the molecule is a mystery, demand shows up as research: new patents, new chemistry, new discovery programs. When the molecule is known and the world simply wants oceans of it, demand shows up as construction — plants, reactors, reagent contracts, and hiring.
And peptide capacity is expensive and slow to build. A single new facility can run past half a billion dollars, and it can't be conjured overnight: specialized reactors, solvent-recovery infrastructure, purification suites, and — crucially — people who actually know how to run large-scale peptide synthesis are all in short supply. That combination of high capital cost and long lead time is why manufacturers are pouring money into plants and reagent supply rather than chasing new molecules. It also sharpens the classic make-versus-buy decision: a branded maker can build its own plants, outsource to specialist contract manufacturers, or do both to hedge — and every choice ripples down a supply chain of amino-acid and reagent vendors who must expand in step or become the next bottleneck.
Who this demand actually touches
Because the constraint is manufacturing, the list of who benefits looks nothing like a discovery boom. Start with the peptide-focused contract development and manufacturing organizations — the specialist CDMOs that already run large-scale solid-phase synthesis. They are the most direct beneficiaries: their capacity is the scarce resource, and their edge isn't a molecule but reactors, validated processes, and scarce operator expertise.
One layer upstream sit the reagent and protected-amino-acid suppliers, plus the makers of coupling reagents, resins, and the solvents the process drinks by the ton. When raw materials dominate the cost of a peptide, these vendors are not a footnote — they are load-bearing, and their ability to scale can gate the whole industry. Downstream sit the fill-finish and drug-product players: an injectable GLP-1 still has to be formulated, filled into vials or pens, and packaged — sterile finishing capacity that is its own separate constraint. And at the center are the branded makers, whose capital-allocation choices — build, buy, or partner — set the tempo for everyone else. Read together, these are the parties a modality-aware demand read would flag; a molecule-by-molecule small-molecule view would miss them entirely.
The caveats — oral pills, greener chemistry, and cooling demand
None of this is destiny, and a good radar names its own blind spots. The clearest wildcard is the arrival of oral small-molecule GLP-1 candidates. If a pill that hits the same target as the injectable peptides reaches scale, it would pull a slice of this demand back into exactly the small-molecule chemistry — and the conventional supply chain — that the peptide wave routed around. That would show up as the radar lighting up again in its native modality: a reminder that the "peptide vs. small molecule" split is a snapshot, not a law.
Two more caveats sit alongside it. First, the chemistry itself is changing: greener and enzymatic peptide-synthesis methods aim to cut the solvent intensity and waste that make today's process so heavy, and if they mature, part of the "capacity is destiny" story softens into an efficiency story. Second, demand could simply moderate — through competition, pricing pressure, or the ordinary cooling of a hype cycle. The point of tracking modality is not to bet the house on peptides forever; it's to notice, early, when the center of gravity moves — in either direction.
When a radar's silence is the signal
Step back and the GLP-1 case makes a general point about reading demand. We instinctively look for signals as things that appear: a new molecule, a new patent, a new program. But some of the most valuable signals are absences — the places a radar built for one kind of chemistry stays dark because the demand has quietly relocated to another. A small-molecule radar going quiet on the biggest drug story of the decade is not a failure of coverage; it is a precise statement that the money is flowing into a modality the small-molecule lens can't see.
That's why the modality question matters as much as the molecule question. Knowing which molecule the world wants is useful; knowing which kind of thing it wants — small molecule, peptide, biologic — tells you which supply chain is about to strain and whether the real opportunity is discovery or construction. GLP-1 is the loud version of that lesson: the same signal that reads as "settled science, nothing to discover" reads, from the manufacturing side, as one of the largest build-outs pharma has ever attempted. Sometimes the demand signal isn't "what to discover" but "what to build" — and hearing it means listening to what the radar doesn't light up as carefully as to what it does.
Editorial commentary from the Knitify Pharma Demand Radar. Not investment, legal, regulatory, or medical advice.